CANDEL THERAPEUTICS, INC. Variable Lease, Cost
CANDEL THERAPEUTICS, INC. (CADL) reported Variable Lease, Cost of $100.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. variable lease, cost for the quarter ending 2026-06-30 was $100.00K, a 156.41% increase year-over-year.
- CANDEL THERAPEUTICS, INC. variable lease, cost for the quarter ending 2026-03-31 was $67.00K, a 67.50% increase year-over-year.
- CANDEL THERAPEUTICS, INC. variable lease, cost for the quarter ending 2025-12-31 was $100.00K.
- CANDEL THERAPEUTICS, INC. variable lease, cost for the quarter ending 2025-09-30 was $37.00K, a 15.91% decline year-over-year.
- CANDEL THERAPEUTICS, INC. variable lease, cost for fiscal 2025 was $200.00K, a 100.00% increase from fiscal 2024.
- CANDEL THERAPEUTICS, INC. variable lease, cost for fiscal 2024 was $100.00K, a 0.00% change from fiscal 2023.
- CANDEL THERAPEUTICS, INC. variable lease, cost for fiscal 2023 was $100.00K, a 0.00% change from fiscal 2022.
- CANDEL THERAPEUTICS, INC. variable lease, cost for fiscal 2022 was $100.00K.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 9 month as first filed | Variable Lease, Cost 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $100.00K 10-Q · filed 2026-08-13 | $100.00K 10-Q · filed 2026-08-13 | $267.00K derived: sum of 3 quarters · filed 2026-08-13 | $304.00K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $67.00K 10-Q · filed 2026-05-14 | $167.00K derived: sum of 2 quarters · filed 2026-05-14 | $204.00K derived: sum of 3 quarters · filed 2026-05-14 | $243.00K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $137.00K derived: sum of 2 quarters · filed 2026-03-12 | $176.00K derived: sum of 3 quarters · filed 2026-08-13 | $200.00K 10-K · filed 2026-03-12 | |
| 2025-09-30 | $37.00K 10-Q · filed 2025-11-13 | $76.00K derived: sum of 2 quarters · filed 2026-08-13 | $100.00K 10-Q · filed 2025-11-13 | $116.00K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $39.00K 10-Q · filed 2026-08-13 | $80.00K 10-Q · filed 2026-08-13 | $79.00K derived: sum of 3 quarters · filed 2026-08-13 | $123.00K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $40.00K 10-Q · filed 2026-05-14 | $40.00K derived: sum of 2 quarters · filed 2026-05-14 | $84.00K derived: sum of 3 quarters · filed 2026-05-14 | $128.00K derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $44.00K derived: sum of 2 quarters · filed 2026-03-12 | $88.00K derived: sum of 3 quarters · filed 2026-03-12 | $100.00K 10-K · filed 2026-03-12 | |
| 2024-09-30 | $44.00K 10-Q · filed 2025-11-13 | $88.00K derived: sum of 2 quarters · filed 2025-11-13 | $100.00K 10-Q · filed 2025-11-13 | $126.00K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $44.00K 10-Q · filed 2025-08-14 | $83.00K 10-Q · filed 2025-08-14 | $82.00K derived: sum of 3 quarters · filed 2025-08-14 | $117.00K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $38.00K 10-Q · filed 2025-05-13 | $38.00K derived: sum of 2 quarters · filed 2025-05-13 | $73.00K derived: sum of 3 quarters · filed 2025-05-13 | $108.00K derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $35.00K derived: sum of 2 quarters · filed 2025-03-13 | $70.00K derived: sum of 3 quarters · filed 2025-03-13 | $100.00K 10-K · filed 2025-03-13 | |
| 2023-09-30 | $35.00K 10-Q · filed 2024-11-14 | $70.00K derived: sum of 2 quarters · filed 2024-11-14 | $100.00K 10-Q · filed 2024-11-14 | $119.00K derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $35.00K 10-Q · filed 2024-08-13 | $85.00K 10-Q · filed 2024-08-13 | $84.00K derived: sum of 3 quarters · filed 2024-08-13 | $115.00K derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $49.00K 10-Q · filed 2024-05-14 | $49.00K derived: sum of 2 quarters · filed 2024-05-14 | $80.00K derived: sum of 3 quarters · filed 2024-05-14 | $124.00K derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $31.00K derived: sum of 2 quarters · filed 2023-11-09 | $75.00K derived: sum of 3 quarters · filed 2023-11-09 | $100.00K 10-K · filed 2023-03-30 | |
| 2022-09-30 | $31.00K 10-Q · filed 2023-11-09 | $75.00K derived: sum of 2 quarters · filed 2023-11-09 | $100.00K 10-Q · filed 2023-11-09 | $123.00K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $44.00K 10-Q · filed 2023-08-10 | $92.00K 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $47.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |